Attenuation by pergolide of haloperidol-induced striatal dopamine receptor density.
Tardive dyskinesia may result from neuroleptic-induced supersensitivity of striatal dopamine receptors. Alteration of receptor site sensitivity may be a therapeutic goal. Pergolide, a direct acting dopamine agonist, decreased in guinea pigs haloperidol-induced increases in striatal dopamine receptor density both when coadministered and when given following haloperidol. Pergolide down-regulates supersensitive dopamine receptors and should be tested in the treatment of tardive dyskinesia.
D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects*; D004873:Ergolines / Q000494:pharmacology*; D006168:Guinea Pigs; D006220:Haloperidol / Q000494:pharmacology*; D008297:Male; D008566:Membranes / Q000378:metabolism; D010479:Pergolide; D011954:Receptors, Dopamine / Q000187:drug effects*; D013134:Spiperone / Q000378:metabolism
D004873:Ergolines; D011954:Receptors, Dopamine; D010479:Pergolide; D013134:Spiperone; D006220:Haloperidol